Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics
08:31pm, Monday, 11'th Aug 2025
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key met
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
07:56pm, Monday, 11'th Aug 2025
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 11'th Aug 2025
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
07:00am, Tuesday, 22'nd Jul 2025
WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
07:00am, Tuesday, 15'th Jul 2025
WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07:00am, Monday, 07'th Jul 2025
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval
08:03am, Wednesday, 25'th Jun 2025
Anaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephr
WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 24'th Jun 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
11:00pm, Sunday, 08'th Jun 2025
Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, a
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
11:35am, Tuesday, 13'th May 2025
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
06:30pm, Monday, 12'th May 2025
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key me
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
06:20pm, Monday, 12'th May 2025
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 12'th May 2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
04:32pm, Sunday, 04'th May 2025
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, w
